linjc16/ctgov huggingface dataset:
A Common Polymorphism of the SRD5A2 Gene is Not Associated With Male-to-Female and Female-to-Male Transsexualism

Study Overview
=================
Brief Summary
-----------------
Genetic variations, i.e. polymorphisms, may be associated with gender dysphoria, e.g. transsexualism. This study aims to identify such variations.

Detailed Description
-----------------
Context: Early developmental exposure of the brain to sex steroids may play a role in the etiology of transsexualism. Objective: To assess the association between transsexualism and allele and genotype frequencies of the steroid 5-alpha reductase (SRD5A2) Val89Leu polymorphism. Design and Patients: We performed a case-control study of 100 male-to-female (MtF) transsexuals, 47 female-to-male (FtM) transsexuals, 755 male controls, and 915 female controls. DNA was extracted from buccal swabs and genotypes were determined by polymerase chain reaction. Results: SRD5A2 Val89Leu allele frequencies (SRD5A2 V: 137/200 [69%] and SRD5A2 L: 63/200 [31%] vs. SRD5A2 V: 1065/1510 [71%] and SRD5A2 L: 445/1510 [29%], respectively; p=0.6; Odds Ratio [OR] 1.10; 95% Confidence Interval [CI] 0.76-1.58) and genotype distributions (SRD5A2 V/V+V/L: 92/100 [92%] and L/L 8/100 [8%] vs. SRD5A2 V/V+V/L: 683/755 [91%] and L/L 72/755 [9%], respectively, p=0.7; OR 0.82; 95% CI 0.24-2.84) were not significantly different between MtF transsexuals and male controls. SRD5A2 Val89Leu allele frequencies (SRD5A2 V: 70/94 [74%] and SRD5A2 L: 24/94 [26%] vs. SRD5A2 V: 1253/1830 [69%] and SRD5A2 L: 573/1830 [31%], respectively; p=0.3; OR 0.75; 95% CI 0.45-1.26) and genotype distributions (SRD5A2 V/V+V/L: 44/47 [93%] and L/L 3/47 [7%] vs. SRD5A2 V/V+V/L: 823/915 [90%] and L/L 92/915 [10%], respectively, p=0.6; OR 0.61; 95% CI 0.11-3.32) were also not significantly different between FtM transsexuals and female controls. Of note, there was no gender-specific genotype distribution among controls. Conclusions: The SRD5A2 Val89Leu polymorphism is not associated with transsexualism and is no candidate gene of this condition.

Official Title
-----------------
Association Study of a SRD5A2 SNP and Transsexualism.

Conditions
-----------------
Transsexualism

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: transsexual individuals as defined by DSM IV criteria Exclusion Criteria: unwillingness to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Transsexual group<br>Female-to-male and male-to-female transsexuals | |
| Controls<br>Healthy blood donors | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Paramedical Consultation in Telemedicine

Study Overview
=================
Brief Summary
-----------------
Feasibility monocentrique opened study estimating the use of an electronic personalized educational plan (ePEP) for the follow-up by nurses of 50 patients diabetics type 1 during 6 months having an electronic pad.

Official Title
-----------------
Evaluation of Paramedical Consultation in Type 1 Diabetic Patients in Telemedicine

Conditions
-----------------
Type 1 Diabetic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient diabetic type 1 patient with the electronic pad in a smartphone adults children between 12 and 17 years 11 months patient having signed the consent Exclusion Criteria: patient diabetic type 2 patient without the electronic pad in a smartphone children below 12 years old

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patient using the system | The using of the system is estimated by the frequency of dose proposition by electronic pad | 6 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| satisfaction level of the patient and quality of life |  | 6 month | 
| satisfaction level of physician | The satisfaction level of physician about the follow-up by e-PEP | 6 month | 
| satisfaction level of the telemedecin nurse | Evaluation of the satisfaction level of the telemedecin nurse about the follow-up by e-PEP | 6 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Telemedecine, Telemedecine nurse, Delegation of tasks, Type 1 diabetes
Evaluation of an Investigational Lubricant Eye Drop on Lipid Layer Thickness

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effects of an investigational lubricant eye drop on tear film lipid layer thickness of dry eye patients.

Conditions
-----------------
Dry Eye

Intervention / Treatment
-----------------
* Other: ORB Ocular Emulsion
* Other: SootheXP Emollient (Lubricant) Eye Drops


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients (minimum age 18) meeting specific criteria for dry eye. Exclusion Criteria: Use of topical ocular drops within 12 hours of the study visit; or use of topical ocular ointment within 36 hours of the study visit. In addition, cannot use any topical ocular drugs during study period. History or evidence of ocular or systemic medical conditions and/or medications that would confound the evaluation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Right Eye<br>ORB Ocular Emulsion or SootheXP | Other: ORB Ocular Emulsion<br>* lubricant eye drop<br>|
| Other: Left Eye<br>ORB Ocular Emulsion or SootheXP | Other: SootheXP Emollient (Lubricant) Eye Drops<br>* lubricant eye drop<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lipid layer thickness |  | Baseline through 120 minutes post instillation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lipid layer thickness
Pre- and Postoperative Cardiopulmonary Rehabilitation Reduces Complications After Coronary Artery Bypass Surgery: A Randomized Trial

Study Overview
=================
Brief Summary
-----------------
Pre- and postoperative cardiopulmonary rehabilitation reduces complications after coronary artery bypass surgery. This study was conducted as a randomized trial to verify this hypothesis in our institution. ICSC

Official Title
-----------------
Pre- and Postoperative Cardiopulmonary Rehabilitation Reduces Complications After Coronary Artery Bypass Surgery: A Randomized Trial

Conditions
-----------------
Coronary Artery Bypass Surgery

Intervention / Treatment
-----------------
* Behavioral: REHAB (Pre- and postoperative cardiopulmonary rehabilitation)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All CAB patients Exclusion Criteria: SCA in the previous 24h and incapacity of doing light exercise. Valvular patients
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: I<br> | Behavioral: REHAB (Pre- and postoperative cardiopulmonary rehabilitation)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| length of stay in the ICU (in minutes); days on the ward after ICU until hospital discharge; pneumonia with the need for antibiotic treatment; and atrial fibrillation or flutter detected on daily-performed electrocardiograms |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time until oro-tracheal tube (OTT) removal, occurrence of pleural effusion, atelectasis, change in peak-flow (baseline vs. 2 hours after extubation vs. discharge), and changes in the 6-minute-walking distance between enrollment and hospital discharge. |  |  |
Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity

Study Overview
=================
Brief Summary
-----------------
The degree of suppression and subsequent activation of the hypothalamic-pituitary-ovarian axis during the hormone-free interval in combined oral contraceptive (COC) hormone users varies depending on the dose of ethinyl estradiol in the formulation. This variation in activation may be associated with different side effects during the hormone free interval. Progesterone (P) remained suppressed during all 6 COC regimens (<1.8 ng/mL), which indicates continuous contraceptive efficacy during the 7-day hormone free interval of all formulations studied.

Official Title
-----------------
LH, FHS, Estradiol and Progesterone Activity During the 7-Day Hormone-Free Interval of Various Combined Oral Contraceptive Regimens

Conditions
-----------------
Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy

Intervention / Treatment
-----------------
* Drug: combined oral contraceptives


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy, reproductive age women 18 to 35 years old, seeking contraception from the general gynecology clinics of the LAC and USC Medical Center w taking one of 6 possible monophasic COC formulations for at least 3 cycles prior to enrollment regular menstrual cycles prior to COCs Exclusion Criteria: Irregular bleeding bilateral oophorectomy amenorrhea hormone-sensitive cancer concurrent medications known to interfere with steroid metabolism (i.e., barbiturates, phenytoin, carbamazepine, ethosuximide, primidone, rifampin, tetracycline)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy reproductive age women<br>These volunteers were previously taking the oral contraceptives of interest for a minimum of 3 months | Drug: combined oral contraceptives<br> <br> * Other names: ALESSE, LOESTRIN, NORDETTE, ORTHOCEPT, ORTHOCYCLEN, ORTHO NOVUM;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Follicle-stimulating Hormone | mean FSH on day 7 of the pill free interval | Serum blood samples were collected for hormone measurements at the same time daily during the 7 day hormone free interval. |
Autonomic Imbalance and 24-h Blood Pressure Change in Patients With Chronic Renal Disease

Study Overview
=================
Brief Summary
-----------------
Many patients with chronic renal disease show a loss of the nocturnal decline of blood pressure (non-dipper). However, the mechanism is not yet fully understood. We evaluate 24-hour blood pressure in patients with chronic renal disease using an ambulatory blood pressure monitoring device (A & D TM2425). We also analyze the power spectrum of heart rate variability as an index of autonomic cardiovascular modulation using the same device.

Detailed Description
-----------------
The ratio of lower frequency (LF) and higher frequency (HF) heart rate rhythmic oscillations is expressed as an index of sympathovagal balance. Patients with chronic renal disease participate in the study. Blood pressure and power spectrum of heart rate variability for 24 hours are measured when they receive no medication for at least 1 week. The mean waking and sleeping time systolic and diastolic blood pressure are calculated. LF/HF ratios in the chronic renal disease are evaluated to calculate the waking/sleeping ratio for LF/HF.

Official Title
-----------------
Autonomic Imbalance and 24-h Blood Pressure Change in Patients With Chronic Renal Disease

Conditions
-----------------
Diabetes Mellitus, Essential Hypertension, Renal Failure, Chronic Nephropathy

Intervention / Treatment
-----------------
* Device: Ambulatory blood pressure monitoring


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hypertensive patients with diabetes mellitus Hypertensive patients Hypertensive patients with renal disease Patients with chronic renal disease Exclusion Criteria: Cardiac, hematologic or hepatic disease Cerebral infarction or hemorrhage Other major diseases.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Ambulatory blood pressure monitoring|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
An Educational Self-tracking Tool for Identification of SARS-CoV-2 Risk Transmission

Study Overview
=================
Brief Summary
-----------------
One way to empower a community, in epidemic control issues, is to know the first-hand screening tools. There are no evaluations of these home-use tools from the perspective of patient and citizen empowerment and participation. The main objective of this study is to analyze whether a self-tracking and self-tracing tool, developed in a participatory way, increases the risk identification of the disease and the empowerment in terms of risk management of transmission by the participants.

Official Title
-----------------
An Educational Self-tracking Tool for Identification of SARS-CoV-2 Risk Transmission: a Randomised Controlled Trial

Conditions
-----------------
Sars-CoV-2 Infection, Empowerment, Transmission

Intervention / Treatment
-----------------
* Other: Track U


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fluent in Catalan or Spanish, Resident in Catalonia, Signs informed consent, Commitment to use the tool if he/she gets in intervention group. Exclusion Criteria: Language barrier and other conditions that do not allow self-completion of the survey Be a COVID case or contact at the time of recruitment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention : Educational tool<br>self-tracking educational tool (diary) | Other: Track U<br>* Track U diary<br>|
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk identification of SARS-CoV 2 transmission | Risk identification of SARS-CoV 2 transmission | 17 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Empowerment in SARS-CoV 2 transmission | Empowerment in SARS-CoV 2 transmission | 17 days |
Epidemiology of Aeromedical Evacuation

Study Overview
=================
Brief Summary
-----------------
Increasing air travel has resulted in a significant increase in aeromedical evacuation over the past decade. However there is only a small amount of epidemiological data available on the diagnosis, costs and transport characteristics of aeromedical evacuation cases. In the present study Cases of aeromedical evacuation by a relief organization (Workers' Samaritan Federation Germany) were analyzed based on the following criteria: age, sex and diagnosis of the patient, ventilation mode, days of illness before transport, type of transport, flight routes, flying time, flight distance, type of aircraft, type and distance of connecting transport from the destination airport to the final hospital, total cost per repatriation, and costs per flight-minute of each transport type.

Official Title
-----------------
Epidemiology of Aeromedical Evacuation

Conditions
-----------------
Apoplexy, Femoral Neck Fracture, Myocardial Infarction, Subarachnoid Hemorrhage, Polytrauma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: medical emergency and aeromedical evacuation / repatriation Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aeromedical Evacuation, Repatriation
A Retrospective Study to Evaluate the ConforMIS iUni, iDuo & iTotal® KRS

Study Overview
=================
Brief Summary
-----------------
This study is designed to evaluate implant survivorship, patient satisfaction, and patient-reported outcomes of subjects who have undergone surgery with any of the following ConforMIS knee implants: the iUni®, iDuo® or iTotal® Cruciate Retaining (CR) Knee Replacement Systems.

Detailed Description
-----------------
This study is designed to evaluate implant survivorship, patient satisfaction and patient-reported outcomes of subjects who have undergone surgery with any of the following ConforMIS knee implants: the iUni®, iDuo® or iTotal® Cruciate Retaining (CR) Knee Replacement Systems.This study is a retrospective, single-center study, with one single remote follow up contact. Patients will be contacted either by phone or email for a single remote follow-up. Retrospective data will be collected from medical records including pre-operative, operative and any follow up visits which have occurred since implantation as available.

Official Title
-----------------
A Retrospective Study to Evaluate the ConforMIS iUni, iDuo & iTotal® CR (Cruciate Retaining) Knee Replacement Systems

Conditions
-----------------
Osteoarthritis, Knee, Knee Osteoarthritis

Intervention / Treatment
-----------------
* Device: ConforMIS iUni, iDuo, or iTotal (CR)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Previously underwent surgical implantation of a ConforMIS iUni, iDuo or iTotal knee replacement. Subject must be greater than 18 years of age.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients implanted with a ConforMIS device<br>Previously underwent surgical implantation of a ConforMIS iUni, iDuo or iTotal knee replacement | Device: ConforMIS iUni, iDuo, or iTotal (CR)<br>* ConforMIS iUni, iDuo, or iTotal (CR)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survivorship data | Survivorship of the implant--whether or not the patient has had a surgical revision prior to data collection. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient Reported Outcomes | Collected via questionnaires during either an in-office visit or a phone call. The questionnaires are aimed at gauging how satisfied the patient is with the function of their device, if and when they experience pain/stiffness, and if and how their activities of daily living have have been affected. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
osteoarthritis, total knee arthroplasty, TKA, TKR, patient specific, Conformis
Diffusion Weighted Magnetic Resonance Imaging of the Breast During Chemotherapy: Response Evaluation

Study Overview
=================
Brief Summary
-----------------
Evaluation of the response to chemotherapy in breast cancer patients by the use of Diffusion-weighted magnetic resonance imaging of the breast before the start of chemotherapy, after one and 3 cycles of therapy and at the end of the therapy.

Official Title
-----------------
Diffusion Weighted Magnetic Resonance Imaging of the Breast During Chemotherapy: Response Evaluation

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: core biopsy with diagnosis of breast cancer start of neo-adjuvant chemotherapy Exclusion Criteria: magnetic resonance imaging incompatibility
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| women with BRCA and chemotherapy<br>women recently diagnosed with breast cancer and start with neo-adjuvant chemotherapy (6 cycles) before surgery/therapy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response to chemotherapy | outcome is the results of pathology after chemotherapy and surgery. Data will be collected for a period of 1 year. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diffusion-weighted magnetic resonance imaging